Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8630 in asthma on ICS/LABA
NCT06795906Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing AZD8630 Dose A with Placebo (2 arms). Primary endpoints: Adverse Events at day 21, Serious Adverse Events at day 21 and 3 more. Started Jan 2025; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06795906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795906.